Insider buying last 90 days
No open-market insider purchases were filed for DHR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Close on Sep 18, 2026. Page updated Sep 19, 9:16 pm ET.
Danaher trades at $211.81, down 0.3% on the day but up 19.6% over three months and 9.8% over the past year, holding above both its 50-day ($203.83) and 200-day ($201.93) averages. The GekkoIndex reads 52, placing the stock in the Neutral zone, and price sits just 1.1% above Gekko Fair Value of $209.53.
This week's news centers on Danaher's reaffirmed quarterly cash dividend of $0.40 per share, payable 30 October 2026 to holders of record as of 30 September 2026, alongside valuation commentary suggesting the stock may be undervalued relative to fair-value estimates cited in that coverage. Separately, UBS assumed coverage with a buy rating and a $250 price target, at a time the stock traded near $205.23. Comparative pieces have also weighed Danaher against peers on value grounds.
Attention over the next 20 trading days centers on the 20 October earnings date, which falls just outside a typical holding window; the last report showed EPS of $1.94 against a $1.84 estimate but produced a -10.9% reaction, with average absolute moves around earnings near 6.9%. Consensus among 18 firms leans heavily toward buy ratings, with a target of $229.09. Seasonally, the next 20 trading days have averaged -2.5% over five years, rising in just 1 of those years, a pattern worth noting alongside the current gap to fair value.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Danaher scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
Above 50 and 200-day
Close $211.81 is above the 50-day ($203.83) and 200-day ($201.93) averages, and the 50-day is above the 200-day.
See the chart52, Neutral
Reading 52 is in the Neutral zone.
See the GekkoIndex1.1% above
Price is within 5% of Gekko Fair Value (1.1% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 30 days
Next report Oct 20, 2026, 30 days away — outside a typical 20-trading-day hold.
See earnings−2.5% on average
From this point in the calendar, the next 20 trading days averaged −2.5% over 5 years, rising in 1 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Danaher closed at $211.81 on Sep 18, 2026, +9.8% over the past year, inside a 52-week range of $160.93 to $242.80.
Use the left and right arrow keys to read daily values.
Put DHR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Danaher makes and distributes scientific, medical, industrial and commercial products and services on a global scale, working across science and technology fields rather than a single product line. It is best known for grouping this work into instruments, consumables and related services that support research, healthcare diagnosis and resource management.
The company operates through three segments. Life Sciences covers instrumentation such as mass spectrometers, flow cytometry, genomics and lab automation equipment, centrifuges, particle analysis tools and microscopes, along with consumables tied to gene and cell therapy, bioprocessing, and filtration and purification systems; its customers include pharmaceutical and biopharmaceutical firms, food and beverage makers, medical and life sciences companies, universities, medical schools, research institutes and industrial manufacturers. Diagnostics supplies chemistry, immunoassay, microbiology, hematology, molecular, acute care and pathology systems, reagents, consumables, software and support to hospitals, physician offices, reference labs and other care settings. Environmental & Applied Solutions provides instruments, software, consumables and disinfection systems for treating and managing different water types, plus tools for color and appearance management, packaging quality, printing, marking, coding and traceability for consumer, pharmaceutical and industrial goods.
Danaher's shares are listed on the NYSE under the ticker DHR.
Danaher’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52, in the Neutral zone, down 11.3 points over five sessions.
Down 11.3 points over five sessions, from the Accumulation zone.
Reading for Sep 18, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 48 | +1.0% | +2.9% | ||
| Accumulation | 223 | 0.0% | +0.4% | ||
| Neutral (current zone) | 373 | −0.1% | −1.0% | ||
| Distribution | 17 | −0.1% | +1.8% | ||
| Selling | 1 | Too few readings yet | |||
Average DHR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Danaher trades 1.1% above Gekko Fair Value of $209.53, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Danaher shares are worth, recalculated every trading day.
$209.53
Gekko Fair Value, Sep 19, 2026
1.1% above fair value · About fair value
No open-market insider purchases were filed for Danaher, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for DHR in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in DHR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Danaher has been buying back its own shares.
From company filings.
9of the funds Gekko tracks hold DHR.
Danaher reports on Oct 20, 2026, before the open (30 days away), and beat the EPS estimate in 7 of its last 8 reports.
Oct 20, 2026
Expected before the open, 30 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 21, 2026 | $1.94 est $1.84 | $6.27B est $6.12B | −10.9% |
| Apr 21, 2026 | $2.06 est $1.94 | $5.95B est $5.98B | −5.9% |
| Jan 28, 2026 | $2.23 est $2.19 | $6.84B est $6.81B | −6.8% |
| Oct 21, 2025 | $1.89 est $1.72 | $6.05B est $6.00B | +4.7% |
| Jul 22, 2025 | $1.80 est $1.64 | $5.94B est $5.84B | +5.2% |
| Apr 22, 2025 | $1.88 est $1.63 | $5.74B est $5.57B | +6.1% |
| Jan 29, 2025 | $2.14 est $2.14 | $6.54B est $6.45B | −10.0% |
| Oct 22, 2024 | $1.71 est $1.57 | $5.80B est $5.59B | −5.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Danaher is $229.09, +8.2% from the last close, from 18 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 18 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 13 | UBS | $250 | +18.0% |
| Aug 4 | Barclays | $230 | +8.6% |
| Jul 30 | Morgan Stanley | $220 | +3.9% |
| Jul 27 | Morgan Stanley | $220 | +3.9% |
| Jul 27 | Jefferies | $210 | −0.9% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Sep 19, Danaher averaged −2.5% across the last 5 years, rising in 1 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.5% | 0 of 5 |
| Next 10 trading days | −0.8% | 2 of 5 |
| Next 15 trading days | −2.7% | 1 of 5 |
| Next 20 trading days | −2.5% | 1 of 5 |
| Next 30 trading days | −5.8% | 1 of 5 |
For scale, DHR’s typical 20-trading-day move in either direction is about 4.6%.
Danaher’s market cap is $148.9B, with a P/E ratio of 37.2 and revenue of $25.11B over the last twelve months.
Coverage of Danaher this week reads positive: 3 positive, 1 neutral and 0 negative headlines.
Danaher’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 17.1% above |
| ABTAbbott Laboratories | Accumulation | 15.5% below |
| ISRGIntuitive Surgical | Neutral | 12.3% above |
| MDTMedtronic | Neutral | 24.7% below |
| SYKStryker | Buying | 17.1% below |
| BSXBoston Scientific | Accumulation | 35.9% below |
A peer links to its own page where one exists.
Danaher’s market cap is $148.9B at the Sep 18, 2026 close of $211.81, with 703.0M shares outstanding. The shares trade on a P/E ratio of 37.2.
The consensus analyst 12-month price target for Danaher is $229.09, +8.2% from the last close. Of the 18 firms that rated the stock in the last 90 days, 16 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Danaher is about fair value: the Sep 18, 2026 close of $211.81 is 1.1% above Gekko Fair Value of $209.53. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Danaher is expected to report on Oct 20, 2026, before the market opens (30 days away). Analysts expect earnings of $1.91 per share on revenue of $6.55B. Danaher beat the earnings estimate in 7 of its last 8 reports, moving 6.9% on average across the report.
Danaher’s 52-week high is $242.80 and its 52-week low is $160.93; it closed at $211.81 on Sep 18, 2026, +9.8% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.